 Black Diamond Therapeutics, Inc. BDTX, a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today reported financial results for the first quarter ended March 31, 2020, and provided a corporate update. We are pleased with our first quarter progress which included advancing the Phase 12 clinical trial of our lead product candidate BDTX-189 and completing our successful initial public offering, said David M. Epstein, Ph.D., President and CEO. 